One study that analyzed archival tumor samples across seven cancer types showed that in triple-negative breast cancer samples, PD-L2 expression was strongly consistent with PD-L1 expression, with no significantly discordant expression between PD-L1 and PD-L2 in any sample. Here, PDCD1LG2 is linked to triple-negative breast carcinoma.